Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.

Cybin, Inc. +1.08% Pre

Cybin, Inc.

HELP

4.69

4.69

+1.08%

0.00% Pre
Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via